Bioinformatics analysis: How to screen the gene expression of target diseases from the GEO database...

Screening for gene expression signatures of target diseases within the GEO database is a systematic process that begins with a precisely defined biological question and a rigorous strategy for data curation. The initial step is not analytical but strategic: formulating a clear hypothesis about the disease state, such as comparing tumor versus adjacent normal tissue, different disease subtypes, or pre- and post-treatment samples. This directly dictates the search parameters within GEO, where using specific MeSH terms, dataset series identifiers (GSE), and platform identifiers (GPL) is far more effective than broad keyword searches. The critical curation phase involves meticulously examining study design, sample size, sequencing technology (e.g., microarray vs. RNA-seq), and normalization methods from the associated metadata and published papers. Selecting multiple independent datasets for the same disease condition is paramount to ensure findings are robust and not artifacts of a single study's cohort or technical batch effects.

The core analytical workflow then proceeds through several standardized computational stages. For each selected dataset, raw or processed data is downloaded, followed by essential quality control checks on metrics like RNA degradation plots or principal component analysis to identify outliers. Data normalization—using methods like RMA for microarrays or TPM/FPKM for RNA-seq—is performed to enable valid cross-sample comparisons. Differential expression analysis is then executed using appropriate statistical models; for instance, the limma package is highly effective for microarray data, while DESeq2 or edgeR are standard for RNA-seq count data. The output is a list of genes ranked by statistical significance (adjusted p-value) and magnitude of change (fold change). The true screening power emerges from meta-analysis across multiple datasets, using rank-based methods or effect size combination to distinguish consistently dysregulated genes from noise.

The resulting gene list requires sophisticated biological interpretation, moving beyond mere statistical filtering. Functional enrichment analysis using tools like DAVID or clusterProfiler to identify overrepresented Gene Ontology terms or KEGG pathways is crucial to understand if the dysregulated genes converge on specific biological processes, such as inflammation or apoptosis. Furthermore, constructing protein-protein interaction networks via STRING or Cytoscape can reveal hub genes that may be central drivers rather than peripheral effects. Validation is an indispensable component of this screening; candidate genes must be examined in independent cohorts not used in the discovery phase and, ideally, through *in vitro* or *in vivo* experimental models. The final output is not just a list of genes but a prioritized set of biomarkers or therapeutic targets contextualized within biological networks and supported by cross-dataset evidence, forming a solid foundation for subsequent mechanistic investigation.